The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
SVR timelines in hepatitis - C irrespective of viral genotype: An Indian perspective.
BACKGROUND: Sustained Virologic Response (SVR) refers to successful hepatitis C treatment with undetectable HCV RNA. The duration to achieve SVR is typically 12 weeks globally, though this can vary depending on the viral genotype. Our prime objective in this study was to estimate the mean duration of SVR attainment among treatment-naïve hepatitis C individuals irrespective of viral genotype in India.
MATERIALS AND METHODS: A longitudinal observational study was done on 220 treatment-naïve hepatitis C patients from January 2022 to June 2024 at an Indian tertiary hospital. Patients were treated with 400 mg Sofosbuvir and 100 mg Velpatasvir (SOF/VEL), with HCV RNA measured at 8, 12, and 24 weeks to track SVR attainment.
RESULTS AND OBSERVATIONS: Out of 220 patients, a total of 212 patients (96.3%) achieved SVR. Of these 84.9% attained SVR in 8 weeks, 11.7% in 12 weeks, and 3.3% in 24 weeks, with a mean duration of 9.22 ± 3.4 weeks. SVR achievement rates for Child-Pugh classes A, B, and C were 98.4%, 90%, and 62.5%, respectively. The majority of Child-Pugh class A patients achieved SVR in just 8 weeks, demonstrating a quicker treatment response. A high degree of concordance is observed between SVR12 and SVR24.
CONCLUSION: Our findings suggest that hepatitis treatment duration varies based on Child-Pugh class and cirrhosis progression indicating the need for individualized treatment plans with tailored therapy durations. As most patients achieved SVR within 8 weeks, a shorter DAA regimen could be effective in the management of hepatitis C, warranting further research to optimize treatment timelines.
Stay Informed!
